Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
CSPC Pharmaceutical Group ( (HK:1093) ) has shared an update.
CSPC Pharmaceutical Group Limited has announced that its innovative SYH2066 Tablets have received approval from China’s National Medical Products Administration to commence clinical trials. This novel oral small molecule drug targets the respiratory syncytial virus (RSV) and is expected to become a significant therapeutic option, as there are currently no approved small molecule drugs for RSV globally. The approval marks a promising step in the company’s clinical development, potentially enhancing its industry position and offering new treatment possibilities for respiratory infections caused by RSV.
The most recent analyst rating on (HK:1093) stock is a Buy with a HK$12.90 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.
More about CSPC Pharmaceutical Group
CSPC Pharmaceutical Group Limited is a Hong Kong-based company operating in the pharmaceutical industry, focusing on the development and production of innovative drugs. The company specializes in creating chemical drugs and has a market focus on addressing unmet medical needs.
Average Trading Volume: 187,522,746
Technical Sentiment Signal: Buy
Current Market Cap: HK$116.4B
For an in-depth examination of 1093 stock, go to TipRanks’ Overview page.